1. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013
2. Cancer epigenetics, tumor immunity, and immunotherapy;Cao;Trends in cancer,2020
3. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence;Vaddepally;Cancers,2020
4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet (London, England),2019
5. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J. Clin. Oncol. : official journal of the American Society of Clinical Oncology,2019